Status:
TERMINATED
Intracoronary Administration of Levosimendan in Cardiac Surgery Patients
Lead Sponsor:
Tampere University Hospital
Conditions:
Myocardial Stunning
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Incomplete recovery from ischemia causes stunned myocardium. Ischemia may be due to coronary artery disease or aortic cross-clamping during surgery. Stunning leads to myocardial dysfunction. It has be...
Eligibility Criteria
Inclusion
- preoperative LVEF 40% or less
- septal wall thickness more than 11mm
- less than moderate aortic insufficiency
- sinus rhythm before CPB
Exclusion
- oesophageal disease
- known allergy to levosimendan or its metabolites or adjuvants.
Key Trial Info
Start Date :
June 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 11 2019
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01500785
Start Date
June 15 2018
End Date
September 11 2019
Last Update
September 13 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Heart Center Co. Tampere university hospital
Tampere, Finland, 33521